Next-generation thrombolytic agent to drive the acute ischemic stroke (AIS) market
Summary
The acute ischemic stroke (AIS) market is poised for major changes during the forecast window out to 2017. Given the impending patent expiry of Activase/Actilyse, in 2015 and 2016 in the US and 5EU respectively, the current standard of care for AIS patients is expected to lose its leading position. From 2015 onwards, Activase is expected to see declining sales; this is not only attributed to loss of patent protection, and the subsequent erosion from potential biosimilar versions, but is largely a result of the anticipated launch of Lundbecks desmoteplase in 2015.
To order this report:
Email: support@researchonglobalmarkets.com
US: +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com
RELATED LINK: http://www.researchonglobalmarkets.com/opportunityanalyzer-acute-ischemic-stroke-opportunity-analysis-and-forecasts-to-2017.html Highlights
Key Questions Answered
- The AIS market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AIS market?
- The late-stage AIS pipeline remains thin. Which drugs will have a significant impact on the AIS market. Which of these drugs will have the highest CAGR, and why?
- Activase remains the only FDA-approved therapy for AIS? How will the drug treatment rates change over the next five years? What are the key drivers and barriers to this change?
Key Findings
- The main driver of the expansion of the AIS market will be the launch of Lundbecks next-generation thrombolytic agent desmoteplase, which has an extended therapeutic time window of up to nine hours post-stroke onset.
- Other key market drivers include the implementation of telemedicine, rapidly growing and ageing population, resulting in a rise in stroke incidence
- Clinical trials attrition in the late-stage pipeline continues to hamper R&D efforts to bring novel
The acute ischemic stroke (AIS) market is poised for major changes during the forecast window out to 2017. Given the impending patent expiry of Activase/Actilyse, in 2015 and 2016 in the US and 5EU respectively, the current standard of care for AIS patients is expected to lose its leading position. From 2015 onwards, Activase is expected to see declining sales; this is not only attributed to loss of patent protection, and the subsequent erosion from potential biosimilar versions, but is largely a result of the anticipated launch of Lundbecks desmoteplase in 2015.
To order this report:
Email: support@researchonglobalmarkets.com
US: +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com
RELATED LINK: http://www.researchonglobalmarkets.com/opportunityanalyzer-acute-ischemic-stroke-opportunity-analysis-and-forecasts-to-2017.html Highlights
Key Questions Answered
- The AIS market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AIS market?
- The late-stage AIS pipeline remains thin. Which drugs will have a significant impact on the AIS market. Which of these drugs will have the highest CAGR, and why?
- Activase remains the only FDA-approved therapy for AIS? How will the drug treatment rates change over the next five years? What are the key drivers and barriers to this change?
Key Findings
- The main driver of the expansion of the AIS market will be the launch of Lundbecks next-generation thrombolytic agent desmoteplase, which has an extended therapeutic time window of up to nine hours post-stroke onset.
- Other key market drivers include the implementation of telemedicine, rapidly growing and ageing population, resulting in a rise in stroke incidence
- Clinical trials attrition in the late-stage pipeline continues to hamper R&D efforts to bring novel